WuXi Biologics Germany to Improve Capabilities with New Prefilled Syringes Line By Investing.com

LEVERKUSEN, Germany, Nov. 13, 2024 /PRNewswire/ — WuXi Biologics (HK:) (“WuXi Bio”) (2269.HK), a number one international Contract Analysis, Improvement, and Manufacturing Group (CRDMO), introduced that it’s going to improve its drug product (DP) capabilities on the firm’s facility in Leverkusen, Germany, with a brand new sterile filling line for prefilled syringes (PFS) utilizing isolator know-how.

Development of the brand new line will optimize the design of the Leverkusen facility’s manufacturing structure to be extra environment friendly for multi-product CRDMO use. The brand new line, with its functionality to deal with a number of syringe sizes (1 ml, 2.25 ml, and three ml) at a filling fee of as much as 400 syringes per minute, allows versatile GMP manufacturing of no less than 17 million syringes yearly. This will likely be along with the present sterile filling and freeze-drying line that has an annual capability of roughly ten million doses. Development is scheduled to begin not too long ago, with the objective of reaching GMP compliance by 2026.

Dr. Chris Chen, CEO of WuXi Biologics, commented, “The elevated capability in Germany will allow us to continue to meet growing client demand for DP services, especially for prefilled syringes. Such investments further demonstrate our commitment to the  Global Dual Sourcing strategy that ensures materials can be sourced and products manufactured at multiple sites within the company’s global network. As a trusted partner to global healthcare companies and a significant contributor to the local community, we are dedicated to providing efficient and cost-effective processes that enable our clients to bring breakthrough therapies to patients.”

About WuXi Biologics

WuXi Biologics (inventory code: 2269.HK) is a number one international Contract Analysis, Improvement and Manufacturing Group (CRDMO) providing end-to-end options that allow companions to find, develop and manufacture biologics “ from idea to commercialization “ for the advantage of sufferers worldwide.

With over 12,000 expert staff in China, the US, Eire, Germany and Singapore, WuXi Biologics leverages its applied sciences and experience to offer prospects with environment friendly and cost-effective biologics discovery, growth and manufacturing options. As of June 30, 2024, WuXi Biologics is supporting 742 built-in shopper initiatives, together with 16 in industrial manufacturing (excluding COVID CMO and non-COVID dormant CMO initiatives).

WuXi Biologics views Environmental, Social, and Governance (ESG) duties as an integral element of our ethos and enterprise technique, and we goal to grow to be an ESG chief within the biologics CRDMO sector. Our amenities use next-generation biomanufacturing applied sciences and clean-energy sources. We’ve additionally established an ESG committee led by our CEO to steer the excellent ESG technique and its implementation, enhancing our dedication to sustainability.

For extra details about WuXi Biologics, please go to: www.wuxibiologics.com.

Contacts

Media
[email protected]

Business
[email protected]